Mehanna Hisham, Al-Maqbili Taleb, Carter Ben, Martin Emma, Campain Nicholas, Watkinson John, McCabe Chris, Boelaert Kristien, Franklyn Jayne A
Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom; Cancer Research Clinical Trials Unit, School of Cancer Sciences (B.C., E.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom; University Hospitals Birmingham NHS Foundation Trust (J.W.), University of Birmingham, Birmingham B15 2TT, United Kingdom; and School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom.
J Clin Endocrinol Metab. 2014 Aug;99(8):2834-43. doi: 10.1210/jc.2013-2118. Epub 2014 May 14.
There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.
To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC.
Two reviewers performed searches of online databases (1966-2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria.
Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3-6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6-8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0-1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5-11%), with an OR of recurrence of 14.7 (95% CI, 5.6-54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence.
Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC.
关于甲状腺微小乳头状癌(PTMC)是否代表不止一种具有不同预后、需要不同治疗的疾病实体存在争议。
比较偶发性和非偶发性PTMC的特征、预后及与预后相关的因素。
两名评审员检索了在线数据库(1966 - 2012年)、参考文献列表和会议摘要书籍。纳入了对年龄大于16岁、接受过任何针对直径≤10mm的甲状腺乳头状癌治疗的受试者的纵向研究。两名评审员独立筛选摘要和文章,提取数据,并使用英国国家临床优化研究所和PRISMA标准评估研究质量。
在检索到的1102篇摘要中,对262项研究进行了评审,纳入了17项研究,共3523名受试者,平均随访70个月,总随访人年数为21329人年。其中包括854例偶发性PTMC受试者(随访4800人年;平均肿瘤大小4.6mm[范围3.3 - 6.7mm])和2669例非偶发性PTMC病例(随访16529人年;平均肿瘤大小6.9mm[范围5.6 - 8.0mm])。偶发性PTMC组的复发率(0.5%;95%置信区间[CI],0 - 1%,P <.001)显著低于非偶发性PTMC组(7.9%;95%CI,5 - 11%),非偶发性PTMC与偶发性PTMC相比,复发的比值比为14.7(95%CI,5.6 - 54.8,P <.001)。80%(126/157)的复发病例有淋巴结受累。在meta回归分析中,年龄、性别、大小、肿瘤多灶性、淋巴结受累情况和治疗方式与复发无显著相关性。
我们的meta分析有力地表明至少存在两种不同的PTMC实体。偶发性PTMC具有不同的临床特征,且复发率远低于非偶发性PTMC,这表明应重新考虑管理方案。需要进行更多具有标准化数据收集的研究,以探索非偶发性PTMC亚组之间的潜在差异。